Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
CIN-103 by Cinphloro Pharma for Irritable Bowel Syndrome: Likelihood of Approval
CIN-103 is under clinical development by Cinphloro Pharma and currently in Phase II for Irritable Bowel Syndrome. According to GlobalData,...